TDN, in particular, may represent a complementary anti-obesity or anti-diabetes agent with the benefits of weight and glucose control, but without the gastrointestinal side effects that often limit GLP-1 therapies
In cases where headaches significantly impact quality of life despite optimization efforts, switching to an alternative agent or considering different therapeutic approaches may be necessary
In PD patients there are reports of decreased CSF post-proline cleaving enzyme (Hagihara and Nagatsu, 1987), increased dipeptidyl-aminopeptidase II (Hagihara et al., 1987), normal dipeptidyl-aminopeptidase IV (Hagihara et al., 1987), and normal glutamic oxaloacetic transaminase (GOT) (Steen and Thomas, 1962
When applied to the scalp or used systemically, they influence key processes that affect hair health